PDCD1 and colorectal carcinoma: As ICI monotherapy has shown limited efficacy in patients with CRC, ICIs combined with other therapies such as chemotherapy are being applied to provide synergistic prognostic benefits, including enhancing the anticancer efficacy of anti-PD-1/PD-L1-based immunotherapy [16].